Tesamorelin holds a distinction almost no other peptide in this space can claim: it is FDA-approved, with phase 3 trial data behind it, specifically for reducing visceral fat. That is the deep belly fat wrapped around the organs, the kind most strongly tied to metabolic risk, and tesamorelin targets it directly while leaving lean mass intact. For body composition backed by hard clinical evidence, it stands in a category of its own.
What tesamorelin is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It uses the full-length GHRH sequence with a stabilizing modification that makes it more durable than the body’s natural version. Rather than injecting growth hormone directly, tesamorelin signals the pituitary gland to release the body’s own growth hormone in natural pulses, which raises IGF-1, the downstream driver of growth hormone’s benefits, without the artificial spikes that come from injected hGH.
What the research shows
Tesamorelin earned its FDA approval (as Egrifta) on the strength of large, rigorous trials. The pivotal study by Falutz and colleagues, published in the New England Journal of Medicine in 2007, randomized 412 adults with abdominal fat accumulation to tesamorelin or placebo over 26 weeks. The result was a roughly 15% reduction in visceral adipose tissue, measured by CT scan, while placebo showed no benefit. Pooled analysis across two phase 3 trials totaling more than 800 participants confirmed visceral fat reductions in the range of 15 to 18%.
Two details make this evidence stand out. First, tesamorelin selectively targets visceral fat while preserving subcutaneous fat and lean mass, so the body composition shift is exactly the one people want. Second, the trials used CT-measured visceral fat as the endpoint, a far harder and more precise measure than BMI or waist size. Alongside the fat reduction, participants showed the sustained rise in IGF-1 that supports protein synthesis and tissue repair.
How it works
Tesamorelin works upstream, at the GHRH receptor on the pituitary. By stimulating the gland to release growth hormone in its natural pulsing rhythm, it raises growth hormone and IGF-1 in a way the body recognizes as normal. Elevated growth hormone drives lipolysis (the breakdown of fat) in visceral fat stores while supporting lean tissue, which is why the trials showed fat coming off the midsection specifically. Because it asks the pituitary to do its own job rather than bypassing it, the effect is measured and physiologic.
Quick facts
| Tesamorelin | |
|---|---|
| Type | Synthetic GHRH analog (full-length, stabilized) |
| Regulatory status | FDA-approved (Egrifta) for visceral fat in lipodystrophy |
| Best known for | Selective visceral fat reduction |
| Trial result | ~15-18% visceral fat reduction at 26 weeks |
| Also raises | IGF-1, supporting lean mass and tissue repair |
| Often paired with | A GHRP such as Ipamorelin (dual GH pathways) |
| Form | Lyophilized powder, reconstituted before use |
What to look for when buying
Because tesamorelin has a real pharmaceutical pedigree, research-grade material should be held to a matching standard. Look for a Certificate of Analysis (COA) from third-party testing and an HPLC-MS purity figure of 99% or higher. Every batch of Marek Pharma’s tesamorelin is HPLC-MS tested with a COA, lyophilized for stability, and ships from within Canada.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359-2370.
- Falutz J, et al. Effects of tesamorelin on visceral fat: pooled phase 3 analysis. Journal of Clinical Endocrinology and Metabolism, 2010.
- FDA Prescribing Information, Egrifta (tesamorelin for injection).
For laboratory and research use only.